Baker Bros. Advisors LP Krystal Biotech, Inc. Transaction History

Baker Bros. Advisors LP

$7.52 Billion
Q2 2024

A detailed history of Baker Bros. Advisors LP transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Baker Bros. Advisors LP holds 169,934 shares of KRYS stock, worth $31.3 Million. This represents 0.41% of its overall portfolio holdings.

Number of Shares

169,934

Previous 169,934 -0.0%

Holding current value

$31.3 Million

Previous $30.2 Million 3.21%

% of portfolio

0.41%

Previous 0.38%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$78.48 - $130.32 $10.4 Million - $17.3 Million	-132,782 Reduced 43.86%	169,934 $20 Million
Q4 2022 Feb 14, 2023	SELL	$63.14 - $79.9 $7.54 Million - $9.55 Million	-119,469 Reduced 28.3%	302,716 $24 Million
Q3 2022 Nov 14, 2022	SELL	$64.85 - $82.4 $25 Million - $31.8 Million	-385,550 Reduced 47.73%	422,185 $29.4 Million
Q4 2021 Feb 14, 2022	BUY	$39.81 - $88.24 $7.96 Million - $17.6 Million	200,000 Added 32.91%	807,735 $56.5 Million
Q2 2021 Aug 16, 2021	SELL	$62.14 - $81.82 $9.49 Million - $12.5 Million	-152,677 Reduced 20.08%	607,735 $41.3 Million
Q1 2021 May 17, 2021	BUY	$59.42 - $85.46 $3.66 Million - $5.26 Million	61,538 Added 8.81%	760,412 $58.6 Million
Q4 2020 Feb 16, 2021	SELL	$40.64 - $61.38 $3.1 Million - $4.68 Million	-76,318 Reduced 9.85%	698,874 $41.9 Million
Q3 2020 Nov 16, 2020	SELL	$37.76 - $48.49 $1.6 Million - $2.06 Million	-42,439 Reduced 5.19%	775,192 $33.4 Million
Q2 2020 Aug 14, 2020	SELL	$37.03 - $60.0 $4.77 Million - $7.73 Million	-128,840 Reduced 13.61%	817,631 $33.9 Million
Q1 2020 May 15, 2020	SELL	$35.02 - $65.64 $3.09 Million - $5.79 Million	-88,203 Reduced 8.52%	946,471 $40.9 Million
Q2 2019 Aug 14, 2019	BUY	$27.2 - $41.2 $6.8 Million - $10.3 Million	250,000 Added 31.86%	1,034,674 $41.7 Million
Q4 2018 Feb 13, 2019	BUY	$15.03 - $25.38 $10.1 Million - $17 Million	670,000 Added 584.26%	784,674 $16.3 Million
Q3 2018 Nov 14, 2018	SELL	$14.43 - $21.0 $1.23 Million - $1.79 Million	-85,326 Reduced 42.66%	114,674 $2.02 Million
Q3 2017 Nov 14, 2017	BUY	$9.75 - $10.64 $1.95 Million - $2.13 Million	200,000	200,000 $1.99 Million

Others Institutions Holding KRYS

# of Institutions

266

Shares Held

25M

Call Options Held

270K

Put Options Held

172K

View Full List

About Krystal Biotech, Inc.

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $4.73B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

More about KRYS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Baker Bros. Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Baker Bros. Advisors LP with notifications on news.

Account

Baker Bros. Advisors LP Krystal Biotech, Inc. Transaction History